nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylprednisolone—ABCB1—Sorafenib—thyroid cancer	0.107	0.281	CbGbCtD
Methylprednisolone—CYP3A4—Vandetanib—thyroid cancer	0.106	0.279	CbGbCtD
Methylprednisolone—ABCB1—Doxorubicin—thyroid cancer	0.0647	0.17	CbGbCtD
Methylprednisolone—CYP3A4—Sorafenib—thyroid cancer	0.0639	0.168	CbGbCtD
Methylprednisolone—CYP3A4—Doxorubicin—thyroid cancer	0.0388	0.102	CbGbCtD
Methylprednisolone—Neuropathy peripheral—Sorafenib—thyroid cancer	0.00206	0.00345	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00206	0.00345	CcSEcCtD
Methylprednisolone—Folliculitis—Doxorubicin—thyroid cancer	0.00205	0.00343	CcSEcCtD
Methylprednisolone—Embolism—Doxorubicin—thyroid cancer	0.00201	0.00335	CcSEcCtD
Methylprednisolone—Hypercalcaemia—Epirubicin—thyroid cancer	0.002	0.00335	CcSEcCtD
Methylprednisolone—Infection—Vandetanib—thyroid cancer	0.00198	0.00331	CcSEcCtD
Methylprednisolone—Hepatomegaly—Epirubicin—thyroid cancer	0.00197	0.00329	CcSEcCtD
Methylprednisolone—Nervous system disorder—Vandetanib—thyroid cancer	0.00195	0.00327	CcSEcCtD
Methylprednisolone—Skin disorder—Vandetanib—thyroid cancer	0.00193	0.00323	CcSEcCtD
Methylprednisolone—Haemoglobin—Sorafenib—thyroid cancer	0.0019	0.00318	CcSEcCtD
Methylprednisolone—Haemorrhage—Sorafenib—thyroid cancer	0.00189	0.00316	CcSEcCtD
Methylprednisolone—Neuritis—Epirubicin—thyroid cancer	0.00186	0.00312	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Sorafenib—thyroid cancer	0.00186	0.00311	CcSEcCtD
Methylprednisolone—Hypercalcaemia—Doxorubicin—thyroid cancer	0.00185	0.0031	CcSEcCtD
Methylprednisolone—Hepatomegaly—Doxorubicin—thyroid cancer	0.00182	0.00304	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00181	0.00303	CcSEcCtD
Methylprednisolone—Fungal infection—Epirubicin—thyroid cancer	0.0018	0.00301	CcSEcCtD
Methylprednisolone—Insomnia—Vandetanib—thyroid cancer	0.0018	0.00301	CcSEcCtD
Methylprednisolone—Paraesthesia—Vandetanib—thyroid cancer	0.00179	0.00299	CcSEcCtD
Methylprednisolone—Necrosis—Epirubicin—thyroid cancer	0.00177	0.00296	CcSEcCtD
Methylprednisolone—Abscess—Epirubicin—thyroid cancer	0.00176	0.00294	CcSEcCtD
Methylprednisolone—Cardiac disorder—Sorafenib—thyroid cancer	0.00175	0.00293	CcSEcCtD
Methylprednisolone—Dyspepsia—Vandetanib—thyroid cancer	0.00175	0.00293	CcSEcCtD
Methylprednisolone—Neuritis—Doxorubicin—thyroid cancer	0.00172	0.00288	CcSEcCtD
Methylprednisolone—Glycosuria—Epirubicin—thyroid cancer	0.00172	0.00287	CcSEcCtD
Methylprednisolone—Fatigue—Vandetanib—thyroid cancer	0.00172	0.00287	CcSEcCtD
Methylprednisolone—Angiopathy—Sorafenib—thyroid cancer	0.00172	0.00287	CcSEcCtD
Methylprednisolone—Immune system disorder—Sorafenib—thyroid cancer	0.00171	0.00286	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Sorafenib—thyroid cancer	0.0017	0.00285	CcSEcCtD
Methylprednisolone—Petechiae—Epirubicin—thyroid cancer	0.00169	0.00283	CcSEcCtD
Methylprednisolone—Arrhythmia—Sorafenib—thyroid cancer	0.00169	0.00282	CcSEcCtD
Methylprednisolone—Fungal infection—Doxorubicin—thyroid cancer	0.00167	0.00279	CcSEcCtD
Methylprednisolone—Mental disorder—Sorafenib—thyroid cancer	0.00166	0.00277	CcSEcCtD
Methylprednisolone—Erythema—Sorafenib—thyroid cancer	0.00165	0.00275	CcSEcCtD
Methylprednisolone—Malnutrition—Sorafenib—thyroid cancer	0.00165	0.00275	CcSEcCtD
Methylprednisolone—Necrosis—Doxorubicin—thyroid cancer	0.00164	0.00274	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00163	0.00272	CcSEcCtD
Methylprednisolone—Abscess—Doxorubicin—thyroid cancer	0.00163	0.00272	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of Androgen receptor activity—TRIM24—thyroid cancer	0.00159	0.0724	CbGpPWpGaD
Methylprednisolone—Glycosuria—Doxorubicin—thyroid cancer	0.00159	0.00266	CcSEcCtD
Methylprednisolone—Amenorrhoea—Epirubicin—thyroid cancer	0.00158	0.00265	CcSEcCtD
Methylprednisolone—Abdominal pain—Vandetanib—thyroid cancer	0.00157	0.00263	CcSEcCtD
Methylprednisolone—Petechiae—Doxorubicin—thyroid cancer	0.00156	0.00262	CcSEcCtD
Methylprednisolone—Arthropathy—Epirubicin—thyroid cancer	0.00153	0.00256	CcSEcCtD
Methylprednisolone—Angioedema—Sorafenib—thyroid cancer	0.0015	0.00251	CcSEcCtD
Methylprednisolone—Syncope—Sorafenib—thyroid cancer	0.00148	0.00247	CcSEcCtD
Methylprednisolone—Amenorrhoea—Doxorubicin—thyroid cancer	0.00147	0.00245	CcSEcCtD
Methylprednisolone—Loss of consciousness—Sorafenib—thyroid cancer	0.00145	0.00242	CcSEcCtD
Methylprednisolone—Inflammation—Epirubicin—thyroid cancer	0.00143	0.0024	CcSEcCtD
Methylprednisolone—Asthenia—Vandetanib—thyroid cancer	0.00143	0.00239	CcSEcCtD
Methylprednisolone—Hypertension—Sorafenib—thyroid cancer	0.00142	0.00238	CcSEcCtD
Methylprednisolone—Arthropathy—Doxorubicin—thyroid cancer	0.00142	0.00237	CcSEcCtD
Methylprednisolone—Pruritus—Vandetanib—thyroid cancer	0.00141	0.00236	CcSEcCtD
Methylprednisolone—Arthralgia—Sorafenib—thyroid cancer	0.0014	0.00234	CcSEcCtD
Methylprednisolone—Myalgia—Sorafenib—thyroid cancer	0.0014	0.00234	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00139	0.00233	CcSEcCtD
Methylprednisolone—Hiccups—Epirubicin—thyroid cancer	0.00139	0.00233	CcSEcCtD
Methylprednisolone—Diarrhoea—Vandetanib—thyroid cancer	0.00136	0.00228	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Sorafenib—thyroid cancer	0.00134	0.00225	CcSEcCtD
Methylprednisolone—NR3C1—Nuclear Receptors—THRB—thyroid cancer	0.00134	0.0609	CbGpPWpGaD
Methylprednisolone—Infection—Sorafenib—thyroid cancer	0.00133	0.00223	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CITED1—thyroid cancer	0.00133	0.0607	CbGpPWpGaD
Methylprednisolone—Skin exfoliation—Epirubicin—thyroid cancer	0.00133	0.00222	CcSEcCtD
Methylprednisolone—Inflammation—Doxorubicin—thyroid cancer	0.00133	0.00222	CcSEcCtD
Methylprednisolone—Shock—Sorafenib—thyroid cancer	0.00132	0.00221	CcSEcCtD
Methylprednisolone—Fluid retention—Epirubicin—thyroid cancer	0.00132	0.00221	CcSEcCtD
Methylprednisolone—Nervous system disorder—Sorafenib—thyroid cancer	0.00132	0.0022	CcSEcCtD
Methylprednisolone—Dizziness—Vandetanib—thyroid cancer	0.00132	0.0022	CcSEcCtD
Methylprednisolone—Neuropathy—Epirubicin—thyroid cancer	0.00131	0.00218	CcSEcCtD
Methylprednisolone—Skin disorder—Sorafenib—thyroid cancer	0.0013	0.00218	CcSEcCtD
Methylprednisolone—Hiccups—Doxorubicin—thyroid cancer	0.00129	0.00215	CcSEcCtD
Methylprednisolone—Oesophagitis—Epirubicin—thyroid cancer	0.00127	0.00213	CcSEcCtD
Methylprednisolone—Vomiting—Vandetanib—thyroid cancer	0.00127	0.00212	CcSEcCtD
Methylprednisolone—Ecchymosis—Epirubicin—thyroid cancer	0.00126	0.0021	CcSEcCtD
Methylprednisolone—Rash—Vandetanib—thyroid cancer	0.00126	0.0021	CcSEcCtD
Methylprednisolone—Dermatitis—Vandetanib—thyroid cancer	0.00125	0.0021	CcSEcCtD
Methylprednisolone—NR3C1—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.00125	0.0568	CbGpPWpGaD
Methylprednisolone—Headache—Vandetanib—thyroid cancer	0.00125	0.00209	CcSEcCtD
Methylprednisolone—Pulmonary oedema—Epirubicin—thyroid cancer	0.00124	0.00207	CcSEcCtD
Methylprednisolone—Skin exfoliation—Doxorubicin—thyroid cancer	0.00123	0.00206	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00122	0.00205	CcSEcCtD
Methylprednisolone—Fluid retention—Doxorubicin—thyroid cancer	0.00122	0.00204	CcSEcCtD
Methylprednisolone—Neuropathy—Doxorubicin—thyroid cancer	0.00121	0.00202	CcSEcCtD
Methylprednisolone—Nausea—Vandetanib—thyroid cancer	0.00118	0.00198	CcSEcCtD
Methylprednisolone—Dyspepsia—Sorafenib—thyroid cancer	0.00118	0.00198	CcSEcCtD
Methylprednisolone—Oesophagitis—Doxorubicin—thyroid cancer	0.00118	0.00197	CcSEcCtD
Methylprednisolone—Thrombophlebitis—Epirubicin—thyroid cancer	0.00117	0.00195	CcSEcCtD
Methylprednisolone—Ecchymosis—Doxorubicin—thyroid cancer	0.00116	0.00195	CcSEcCtD
Methylprednisolone—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.00116	0.00194	CcSEcCtD
Methylprednisolone—Diabetes mellitus—Epirubicin—thyroid cancer	0.00116	0.00194	CcSEcCtD
Methylprednisolone—Fatigue—Sorafenib—thyroid cancer	0.00116	0.00194	CcSEcCtD
Methylprednisolone—Pulmonary oedema—Doxorubicin—thyroid cancer	0.00115	0.00192	CcSEcCtD
Methylprednisolone—Cardiac failure congestive—Epirubicin—thyroid cancer	0.00111	0.00186	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Sorafenib—thyroid cancer	0.0011	0.00184	CcSEcCtD
Methylprednisolone—Thrombophlebitis—Doxorubicin—thyroid cancer	0.00108	0.00181	CcSEcCtD
Methylprednisolone—Increased appetite—Epirubicin—thyroid cancer	0.00108	0.0018	CcSEcCtD
Methylprednisolone—Diabetes mellitus—Doxorubicin—thyroid cancer	0.00107	0.0018	CcSEcCtD
Methylprednisolone—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.00107	0.0018	CcSEcCtD
Methylprednisolone—Urticaria—Sorafenib—thyroid cancer	0.00107	0.00178	CcSEcCtD
Methylprednisolone—Abdominal pain—Sorafenib—thyroid cancer	0.00106	0.00178	CcSEcCtD
Methylprednisolone—NR3C1—Nuclear Receptor transcription pathway—THRB—thyroid cancer	0.00106	0.0481	CbGpPWpGaD
Methylprednisolone—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.00104	0.00175	CcSEcCtD
Methylprednisolone—Cardiac failure—Epirubicin—thyroid cancer	0.00103	0.00173	CcSEcCtD
Methylprednisolone—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.00103	0.00172	CcSEcCtD
Methylprednisolone—Osteoarthritis—Epirubicin—thyroid cancer	0.00101	0.00169	CcSEcCtD
Methylprednisolone—Increased appetite—Doxorubicin—thyroid cancer	0.000995	0.00166	CcSEcCtD
Methylprednisolone—Affect lability—Epirubicin—thyroid cancer	0.000994	0.00166	CcSEcCtD
Methylprednisolone—Hypersensitivity—Sorafenib—thyroid cancer	0.00099	0.00165	CcSEcCtD
Methylprednisolone—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000966	0.00161	CcSEcCtD
Methylprednisolone—Asthenia—Sorafenib—thyroid cancer	0.000964	0.00161	CcSEcCtD
Methylprednisolone—Cardiac arrest—Epirubicin—thyroid cancer	0.00096	0.00161	CcSEcCtD
Methylprednisolone—Cardiac failure—Doxorubicin—thyroid cancer	0.000958	0.0016	CcSEcCtD
Methylprednisolone—Mood swings—Epirubicin—thyroid cancer	0.000957	0.0016	CcSEcCtD
Methylprednisolone—Pruritus—Sorafenib—thyroid cancer	0.00095	0.00159	CcSEcCtD
Methylprednisolone—Osteoarthritis—Doxorubicin—thyroid cancer	0.000935	0.00156	CcSEcCtD
Methylprednisolone—Affect lability—Doxorubicin—thyroid cancer	0.00092	0.00154	CcSEcCtD
Methylprednisolone—Diarrhoea—Sorafenib—thyroid cancer	0.000919	0.00154	CcSEcCtD
Methylprednisolone—Breast disorder—Epirubicin—thyroid cancer	0.000913	0.00153	CcSEcCtD
Methylprednisolone—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000891	0.00149	CcSEcCtD
Methylprednisolone—Muscular weakness—Epirubicin—thyroid cancer	0.000891	0.00149	CcSEcCtD
Methylprednisolone—Cardiac arrest—Doxorubicin—thyroid cancer	0.000889	0.00149	CcSEcCtD
Methylprednisolone—Dizziness—Sorafenib—thyroid cancer	0.000888	0.00149	CcSEcCtD
Methylprednisolone—Mood swings—Doxorubicin—thyroid cancer	0.000885	0.00148	CcSEcCtD
Methylprednisolone—NR3C1—Endoderm Differentiation—NKX2-1—thyroid cancer	0.000881	0.0401	CbGpPWpGaD
Methylprednisolone—NR3C1—Transcription factor regulation in adipogenesis—RXRA—thyroid cancer	0.000881	0.0401	CbGpPWpGaD
Methylprednisolone—Abdominal distension—Epirubicin—thyroid cancer	0.000879	0.00147	CcSEcCtD
Methylprednisolone—Pancreatitis—Epirubicin—thyroid cancer	0.000856	0.00143	CcSEcCtD
Methylprednisolone—Vomiting—Sorafenib—thyroid cancer	0.000854	0.00143	CcSEcCtD
Methylprednisolone—Rash—Sorafenib—thyroid cancer	0.000847	0.00142	CcSEcCtD
Methylprednisolone—Dermatitis—Sorafenib—thyroid cancer	0.000846	0.00142	CcSEcCtD
Methylprednisolone—Breast disorder—Doxorubicin—thyroid cancer	0.000845	0.00141	CcSEcCtD
Methylprednisolone—Headache—Sorafenib—thyroid cancer	0.000842	0.00141	CcSEcCtD
Methylprednisolone—Muscular weakness—Doxorubicin—thyroid cancer	0.000824	0.00138	CcSEcCtD
Methylprednisolone—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000824	0.00138	CcSEcCtD
Methylprednisolone—Abdominal distension—Doxorubicin—thyroid cancer	0.000813	0.00136	CcSEcCtD
Methylprednisolone—Nausea—Sorafenib—thyroid cancer	0.000798	0.00133	CcSEcCtD
Methylprednisolone—Weight increased—Epirubicin—thyroid cancer	0.000794	0.00133	CcSEcCtD
Methylprednisolone—Pancreatitis—Doxorubicin—thyroid cancer	0.000792	0.00132	CcSEcCtD
Methylprednisolone—Infestation NOS—Epirubicin—thyroid cancer	0.000778	0.0013	CcSEcCtD
Methylprednisolone—Infestation—Epirubicin—thyroid cancer	0.000778	0.0013	CcSEcCtD
Methylprednisolone—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000763	0.00128	CcSEcCtD
Methylprednisolone—Sweating—Epirubicin—thyroid cancer	0.000746	0.00125	CcSEcCtD
Methylprednisolone—Weight increased—Doxorubicin—thyroid cancer	0.000735	0.00123	CcSEcCtD
Methylprednisolone—Infestation—Doxorubicin—thyroid cancer	0.00072	0.0012	CcSEcCtD
Methylprednisolone—Infestation NOS—Doxorubicin—thyroid cancer	0.00072	0.0012	CcSEcCtD
Methylprednisolone—Bradycardia—Epirubicin—thyroid cancer	0.000711	0.00119	CcSEcCtD
Methylprednisolone—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000706	0.00118	CcSEcCtD
Methylprednisolone—Haemoglobin—Epirubicin—thyroid cancer	0.000702	0.00117	CcSEcCtD
Methylprednisolone—Rhinitis—Epirubicin—thyroid cancer	0.000701	0.00117	CcSEcCtD
Methylprednisolone—Haemorrhage—Epirubicin—thyroid cancer	0.000699	0.00117	CcSEcCtD
Methylprednisolone—Sweating—Doxorubicin—thyroid cancer	0.00069	0.00115	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Epirubicin—thyroid cancer	0.000687	0.00115	CcSEcCtD
Methylprednisolone—Visual impairment—Epirubicin—thyroid cancer	0.000673	0.00113	CcSEcCtD
Methylprednisolone—Bradycardia—Doxorubicin—thyroid cancer	0.000658	0.0011	CcSEcCtD
Methylprednisolone—Eye disorder—Epirubicin—thyroid cancer	0.000653	0.00109	CcSEcCtD
Methylprednisolone—Haemoglobin—Doxorubicin—thyroid cancer	0.00065	0.00109	CcSEcCtD
Methylprednisolone—Cardiac disorder—Epirubicin—thyroid cancer	0.000648	0.00108	CcSEcCtD
Methylprednisolone—Rhinitis—Doxorubicin—thyroid cancer	0.000648	0.00108	CcSEcCtD
Methylprednisolone—Haemorrhage—Doxorubicin—thyroid cancer	0.000647	0.00108	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000635	0.00106	CcSEcCtD
Methylprednisolone—Angiopathy—Epirubicin—thyroid cancer	0.000634	0.00106	CcSEcCtD
Methylprednisolone—Immune system disorder—Epirubicin—thyroid cancer	0.000631	0.00106	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Epirubicin—thyroid cancer	0.00063	0.00105	CcSEcCtD
Methylprednisolone—Arrhythmia—Epirubicin—thyroid cancer	0.000624	0.00104	CcSEcCtD
Methylprednisolone—Visual impairment—Doxorubicin—thyroid cancer	0.000623	0.00104	CcSEcCtD
Methylprednisolone—Mental disorder—Epirubicin—thyroid cancer	0.000612	0.00102	CcSEcCtD
Methylprednisolone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—thyroid cancer	0.000609	0.0277	CbGpPWpGaD
Methylprednisolone—Erythema—Epirubicin—thyroid cancer	0.000608	0.00102	CcSEcCtD
Methylprednisolone—Malnutrition—Epirubicin—thyroid cancer	0.000608	0.00102	CcSEcCtD
Methylprednisolone—Eye disorder—Doxorubicin—thyroid cancer	0.000604	0.00101	CcSEcCtD
Methylprednisolone—Cardiac disorder—Doxorubicin—thyroid cancer	0.0006	0.001	CcSEcCtD
Methylprednisolone—Angiopathy—Doxorubicin—thyroid cancer	0.000587	0.000981	CcSEcCtD
Methylprednisolone—Immune system disorder—Doxorubicin—thyroid cancer	0.000584	0.000977	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000583	0.000974	CcSEcCtD
Methylprednisolone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—RXRA—thyroid cancer	0.000581	0.0264	CbGpPWpGaD
Methylprednisolone—Arrhythmia—Doxorubicin—thyroid cancer	0.000578	0.000966	CcSEcCtD
Methylprednisolone—NR3C1—Nuclear Receptors—RXRA—thyroid cancer	0.000569	0.0259	CbGpPWpGaD
Methylprednisolone—Mental disorder—Doxorubicin—thyroid cancer	0.000566	0.000947	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Epirubicin—thyroid cancer	0.000564	0.000944	CcSEcCtD
Methylprednisolone—Malnutrition—Doxorubicin—thyroid cancer	0.000563	0.000941	CcSEcCtD
Methylprednisolone—Erythema—Doxorubicin—thyroid cancer	0.000563	0.000941	CcSEcCtD
Methylprednisolone—NR3C1—Transcription factor regulation in adipogenesis—PPARG—thyroid cancer	0.000556	0.0253	CbGpPWpGaD
Methylprednisolone—Malaise—Epirubicin—thyroid cancer	0.000549	0.000917	CcSEcCtD
Methylprednisolone—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000548	0.0249	CbGpPWpGaD
Methylprednisolone—Vertigo—Epirubicin—thyroid cancer	0.000546	0.000914	CcSEcCtD
Methylprednisolone—Syncope—Epirubicin—thyroid cancer	0.000545	0.000912	CcSEcCtD
Methylprednisolone—Loss of consciousness—Epirubicin—thyroid cancer	0.000535	0.000894	CcSEcCtD
Methylprednisolone—Convulsion—Epirubicin—thyroid cancer	0.000527	0.000881	CcSEcCtD
Methylprednisolone—Hypertension—Epirubicin—thyroid cancer	0.000525	0.000878	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000522	0.000873	CcSEcCtD
Methylprednisolone—Arthralgia—Epirubicin—thyroid cancer	0.000518	0.000866	CcSEcCtD
Methylprednisolone—Myalgia—Epirubicin—thyroid cancer	0.000518	0.000866	CcSEcCtD
Methylprednisolone—Anxiety—Epirubicin—thyroid cancer	0.000516	0.000863	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000514	0.00086	CcSEcCtD
Methylprednisolone—Discomfort—Epirubicin—thyroid cancer	0.000512	0.000856	CcSEcCtD
Methylprednisolone—Malaise—Doxorubicin—thyroid cancer	0.000508	0.000849	CcSEcCtD
Methylprednisolone—Vertigo—Doxorubicin—thyroid cancer	0.000506	0.000846	CcSEcCtD
Methylprednisolone—Syncope—Doxorubicin—thyroid cancer	0.000505	0.000844	CcSEcCtD
Methylprednisolone—Confusional state—Epirubicin—thyroid cancer	0.000501	0.000837	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Epirubicin—thyroid cancer	0.000496	0.00083	CcSEcCtD
Methylprednisolone—Loss of consciousness—Doxorubicin—thyroid cancer	0.000495	0.000827	CcSEcCtD
Methylprednisolone—Infection—Epirubicin—thyroid cancer	0.000493	0.000825	CcSEcCtD
Methylprednisolone—Shock—Epirubicin—thyroid cancer	0.000488	0.000817	CcSEcCtD
Methylprednisolone—Convulsion—Doxorubicin—thyroid cancer	0.000488	0.000815	CcSEcCtD
Methylprednisolone—Nervous system disorder—Epirubicin—thyroid cancer	0.000487	0.000814	CcSEcCtD
Methylprednisolone—Hypertension—Doxorubicin—thyroid cancer	0.000486	0.000813	CcSEcCtD
Methylprednisolone—Tachycardia—Epirubicin—thyroid cancer	0.000485	0.00081	CcSEcCtD
Methylprednisolone—Skin disorder—Epirubicin—thyroid cancer	0.000482	0.000806	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Epirubicin—thyroid cancer	0.00048	0.000803	CcSEcCtD
Methylprednisolone—Myalgia—Doxorubicin—thyroid cancer	0.000479	0.000801	CcSEcCtD
Methylprednisolone—Arthralgia—Doxorubicin—thyroid cancer	0.000479	0.000801	CcSEcCtD
Methylprednisolone—Anxiety—Doxorubicin—thyroid cancer	0.000477	0.000798	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000476	0.000796	CcSEcCtD
Methylprednisolone—Discomfort—Doxorubicin—thyroid cancer	0.000473	0.000792	CcSEcCtD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—RET—thyroid cancer	0.000465	0.0212	CbGpPWpGaD
Methylprednisolone—Hypotension—Epirubicin—thyroid cancer	0.000464	0.000776	CcSEcCtD
Methylprednisolone—Confusional state—Doxorubicin—thyroid cancer	0.000463	0.000775	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000459	0.000768	CcSEcCtD
Methylprednisolone—Infection—Doxorubicin—thyroid cancer	0.000456	0.000763	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000452	0.000756	CcSEcCtD
Methylprednisolone—Shock—Doxorubicin—thyroid cancer	0.000452	0.000756	CcSEcCtD
Methylprednisolone—Nervous system disorder—Doxorubicin—thyroid cancer	0.00045	0.000753	CcSEcCtD
Methylprednisolone—NR3C1—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.00045	0.0204	CbGpPWpGaD
Methylprednisolone—Insomnia—Epirubicin—thyroid cancer	0.000449	0.000751	CcSEcCtD
Methylprednisolone—Tachycardia—Doxorubicin—thyroid cancer	0.000448	0.00075	CcSEcCtD
Methylprednisolone—Skin disorder—Doxorubicin—thyroid cancer	0.000446	0.000746	CcSEcCtD
Methylprednisolone—Paraesthesia—Epirubicin—thyroid cancer	0.000446	0.000745	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000444	0.000743	CcSEcCtD
Methylprednisolone—Dyspepsia—Epirubicin—thyroid cancer	0.000437	0.000731	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of Androgen receptor activity—RXRA—thyroid cancer	0.000436	0.0198	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.000433	0.0197	CbGpPWpGaD
Methylprednisolone—Hypotension—Doxorubicin—thyroid cancer	0.000429	0.000718	CcSEcCtD
Methylprednisolone—Fatigue—Epirubicin—thyroid cancer	0.000428	0.000716	CcSEcCtD
Methylprednisolone—NR3C1—Circadian Clock—RXRA—thyroid cancer	0.000423	0.0192	CbGpPWpGaD
Methylprednisolone—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000418	0.0007	CcSEcCtD
Methylprednisolone—Insomnia—Doxorubicin—thyroid cancer	0.000415	0.000695	CcSEcCtD
Methylprednisolone—Paraesthesia—Doxorubicin—thyroid cancer	0.000412	0.00069	CcSEcCtD
Methylprednisolone—Feeling abnormal—Epirubicin—thyroid cancer	0.000409	0.000684	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000406	0.000679	CcSEcCtD
Methylprednisolone—Dyspepsia—Doxorubicin—thyroid cancer	0.000404	0.000676	CcSEcCtD
Methylprednisolone—Fatigue—Doxorubicin—thyroid cancer	0.000396	0.000662	CcSEcCtD
Methylprednisolone—Urticaria—Epirubicin—thyroid cancer	0.000394	0.000659	CcSEcCtD
Methylprednisolone—Abdominal pain—Epirubicin—thyroid cancer	0.000392	0.000656	CcSEcCtD
Methylprednisolone—Feeling abnormal—Doxorubicin—thyroid cancer	0.000379	0.000633	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—CDK1—thyroid cancer	0.000376	0.0171	CbGpPWpGaD
Methylprednisolone—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000376	0.000628	CcSEcCtD
Methylprednisolone—Hypersensitivity—Epirubicin—thyroid cancer	0.000366	0.000612	CcSEcCtD
Methylprednisolone—Urticaria—Doxorubicin—thyroid cancer	0.000365	0.00061	CcSEcCtD
Methylprednisolone—Abdominal pain—Doxorubicin—thyroid cancer	0.000363	0.000607	CcSEcCtD
Methylprednisolone—NR3C1—Nuclear Receptors—PPARG—thyroid cancer	0.000359	0.0163	CbGpPWpGaD
Methylprednisolone—Asthenia—Epirubicin—thyroid cancer	0.000356	0.000596	CcSEcCtD
Methylprednisolone—Pruritus—Epirubicin—thyroid cancer	0.000351	0.000587	CcSEcCtD
Methylprednisolone—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000351	0.0159	CbGpPWpGaD
Methylprednisolone—Diarrhoea—Epirubicin—thyroid cancer	0.00034	0.000568	CcSEcCtD
Methylprednisolone—Hypersensitivity—Doxorubicin—thyroid cancer	0.000338	0.000566	CcSEcCtD
Methylprednisolone—Asthenia—Doxorubicin—thyroid cancer	0.00033	0.000551	CcSEcCtD
Methylprednisolone—Dizziness—Epirubicin—thyroid cancer	0.000328	0.000549	CcSEcCtD
Methylprednisolone—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000328	0.0149	CbGpPWpGaD
Methylprednisolone—Pruritus—Doxorubicin—thyroid cancer	0.000325	0.000543	CcSEcCtD
Methylprednisolone—Vomiting—Epirubicin—thyroid cancer	0.000316	0.000528	CcSEcCtD
Methylprednisolone—NR3C1—Circadian Clock—HIF1A—thyroid cancer	0.000314	0.0143	CbGpPWpGaD
Methylprednisolone—Diarrhoea—Doxorubicin—thyroid cancer	0.000314	0.000526	CcSEcCtD
Methylprednisolone—Rash—Epirubicin—thyroid cancer	0.000313	0.000523	CcSEcCtD
Methylprednisolone—Dermatitis—Epirubicin—thyroid cancer	0.000313	0.000523	CcSEcCtD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.000313	0.0142	CbGpPWpGaD
Methylprednisolone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.000311	0.0142	CbGpPWpGaD
Methylprednisolone—Headache—Epirubicin—thyroid cancer	0.000311	0.00052	CcSEcCtD
Methylprednisolone—Dizziness—Doxorubicin—thyroid cancer	0.000304	0.000508	CcSEcCtD
Methylprednisolone—Nausea—Epirubicin—thyroid cancer	0.000295	0.000493	CcSEcCtD
Methylprednisolone—Vomiting—Doxorubicin—thyroid cancer	0.000292	0.000488	CcSEcCtD
Methylprednisolone—Rash—Doxorubicin—thyroid cancer	0.00029	0.000484	CcSEcCtD
Methylprednisolone—Dermatitis—Doxorubicin—thyroid cancer	0.000289	0.000484	CcSEcCtD
Methylprednisolone—Headache—Doxorubicin—thyroid cancer	0.000288	0.000481	CcSEcCtD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000288	0.0131	CbGpPWpGaD
Methylprednisolone—NR3C1—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.000284	0.0129	CbGpPWpGaD
Methylprednisolone—Nausea—Doxorubicin—thyroid cancer	0.000273	0.000456	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—HIF1A—thyroid cancer	0.000259	0.0118	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—TRIM33—thyroid cancer	0.000253	0.0115	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.000245	0.0112	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—SST—thyroid cancer	0.000227	0.0103	CbGpPWpGaD
Methylprednisolone—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000216	0.00983	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—RXRA—thyroid cancer	0.000213	0.00967	CbGpPWpGaD
Methylprednisolone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000211	0.00959	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000191	0.00867	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—THRB—thyroid cancer	0.000183	0.00831	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—HIF1A—thyroid cancer	0.000158	0.00718	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—CCND1—thyroid cancer	0.000157	0.00712	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000153	0.00694	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—PTEN—thyroid cancer	0.000151	0.00688	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000146	0.00664	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000137	0.00621	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—PPARG—thyroid cancer	0.000134	0.00611	CbGpPWpGaD
Methylprednisolone—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000131	0.00594	CbGpPWpGaD
Methylprednisolone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.00013	0.00591	CbGpPWpGaD
Methylprednisolone—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.000126	0.00574	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—TRIM33—thyroid cancer	0.000122	0.00554	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—MEN1—thyroid cancer	0.000116	0.00528	CbGpPWpGaD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000106	0.00482	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—TP53—thyroid cancer	0.000103	0.00469	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—TP53—thyroid cancer	9.09e-05	0.00413	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—THRB—thyroid cancer	8.8e-05	0.004	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	8.4e-05	0.00382	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—RXRA—thyroid cancer	7.77e-05	0.00353	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—thyroid cancer	7.75e-05	0.00353	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—AKT1—thyroid cancer	7.68e-05	0.00349	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—MINPP1—thyroid cancer	6.71e-05	0.00305	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—TPR—thyroid cancer	5.95e-05	0.0027	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—NDUFA13—thyroid cancer	5.71e-05	0.00259	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—RXRA—thyroid cancer	5.63e-05	0.00256	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—MEN1—thyroid cancer	5.59e-05	0.00254	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CHST14—thyroid cancer	5.36e-05	0.00244	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	5.3e-05	0.00241	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	5.3e-05	0.00241	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	5.22e-05	0.00237	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	4.91e-05	0.00223	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—PPARG—thyroid cancer	4.9e-05	0.00223	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—HPGD—thyroid cancer	4.32e-05	0.00197	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	4.17e-05	0.0019	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—MINPP1—thyroid cancer	4.13e-05	0.00188	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	3.97e-05	0.00181	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	3.77e-05	0.00171	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—RXRA—thyroid cancer	3.74e-05	0.0017	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	3.64e-05	0.00165	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—NDUFA13—thyroid cancer	3.52e-05	0.0016	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.34e-05	0.00152	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CHST14—thyroid cancer	3.31e-05	0.0015	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	2.79e-05	0.00127	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—HPGD—thyroid cancer	2.66e-05	0.00121	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—TPR—thyroid cancer	2.48e-05	0.00113	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.48e-05	0.00113	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PRKAR1A—thyroid cancer	2.44e-05	0.00111	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—PPARG—thyroid cancer	2.36e-05	0.00107	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	2.1e-05	0.000954	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.86e-05	0.000845	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—RXRA—thyroid cancer	1.56e-05	0.00071	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—TPR—thyroid cancer	1.53e-05	0.000696	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.51e-05	0.000685	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.15e-05	0.000521	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PPARG—thyroid cancer	9.86e-06	0.000449	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—RXRA—thyroid cancer	9.62e-06	0.000438	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—AKT1—thyroid cancer	9.34e-06	0.000424	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PTGS2—thyroid cancer	7.76e-06	0.000353	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PTEN—thyroid cancer	6.77e-06	0.000308	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PPARG—thyroid cancer	6.08e-06	0.000276	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PTGS2—thyroid cancer	4.78e-06	0.000217	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PTEN—thyroid cancer	4.17e-06	0.00019	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—AKT1—thyroid cancer	3.9e-06	0.000177	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—AKT1—thyroid cancer	2.4e-06	0.000109	CbGpPWpGaD
